GNLX
GENELUX Corp
NASDAQ · Healthcare · Biotechnology · US
$2.45
+1.24%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.42
From 52W high−70.27%
Volume161466.00
Market cap$110.85M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.42
From 52W high
−70.27%
Volume
161466.00
Market cap
$110.85M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
P/E (TTM)
—
RSI (14)
45.8
MomentumView details →
1D Return
+1.24%
YTD Return
−43.92%
SummaryUpdated Jun 1, 2026
Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biopharmaceutical company founded in 2001 and headquartered in Westlake Village, California. The company went public in January 2023 and specializes in developing innovative oncolytic viral immunotherapies designed to treat aggressive and difficult-to-treat solid tumors. Genelux represents a new frontier in cancer treatment, utilizing genetically modified viruses that can selectively target and destroy cancer cells while potentially stimulating the patient's immune system to fight the disease.
Similar companies
Latest newsMore news →